Green tea polyphenols and cancer chemoprevention: Multiple mechanisms and endpoints for phase II trials

Nutrition Reviews

Volumn 62, Issue 5, 2004, Pages 204-211

  Moyers, Susan B ^a,b   Kumar, Nagi B ^a,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TAMPA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer chemoprevention; Catechin; Green tea; Polyphenols

Indexed keywords

CATECHIN; CATECHOL METHYLTRANSFERASE; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GALLOCATECHIN; GLUCURONIDE; METHYL GROUP; METHYLTRANSFERASE; POLYPHENOL DERIVATIVE; SULFATE;

ALLELIC EXCLUSION; ALLELIC VARIABILITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BIOTRANSFORMATION; CANCER PREVENTION; CANCER RESEARCH; CLINICAL TRIAL; DRUG ABSORPTION; DRUG GLUCURONIDATION; DRUG MECHANISM; DRUG SULFATION; GENETIC VARIABILITY; HUMAN; METHYLATION; REVIEW; STRUCTURE ACTIVITY RELATION; TEA;

ANTICARCINOGENIC AGENTS; BIOLOGICAL AVAILABILITY; CAMELLIA SINENSIS; CATECHIN; CATECHOL O-METHYLTRANSFERASE; CLINICAL TRIALS, PHASE II; FLAVONOIDS; HUMANS; MUTATION; PHENOLS; PLANT LEAVES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2542520785     PISSN: 00296643     EISSN: None     Source Type: Journal    
DOI: 10.1301/nr.2004.may.204-211     Document Type: Review

References (69)

1. Wu AH, Yu MC, Tseng CC, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. Int J Cancer. 2003;106:574-579.
2. Ji BT, Chow WH, Hsing AW, et al. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer. 1997;70:255-258.
3. Hoshiyama Y, Kawaguchi T, Miura Y, et al. A prospective study of stomach cancer death in relation to green tea consumption in Japan. Br J Cancer. 2002;87:309-313.
4. Setiawan VW, Zhang ZF, Yu GP, et al. Protective effect of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer. 2001;92:600-604.
5. Zhang M, Binns CW, Lee AH. Tea consumption and ovarian cancer risk: a case-control study in China. Cancer Epidemiol Biomarkers Prev. 2002;11:713-718.
6. Zhong L, Goldberg MS, Gao YT, Hanley JA, Parent ME, Jin F. A population-based case-control study of lung cancer and green tea consumption among women living in Shanghai, China. Epidemiology. 2001;12:695-700.
7. Inoue M, Tajima K, Mizutani M, et al. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett. 2001;167:175-182.
8. Lin JK, Liang YC, Lin-Shiau SY. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem Pharmacol. 1999; 58:911-915.
9. National Cancer Institute, Division of Cancer Prevention and Control, Chemoprevention Branch, and Agent Development Committee. Clinical development plan: tea extracts green tea polyphenols epigallocatechin gallate. J Cell Biochem. 1996;26S: 236-257.
10. Balentine DA, Wiseman SA, Bouwens LCM. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997;37:693-704.
11. Henning SM, Fajardo-Lira C, Lee HW, Youssefian AA, Go VL, Heber D. Catechin content of 18 teas and a green tea extract supplement correlates with the antioxidant capacity. Nutr Cancer. 2003; 45:226-235.
12. Xu M, Dashwood RH. Chemoprevention studies of heterocyclic amine-induced colon carcinogenesis. Cancer Lett. 1999;143:179-183.
13. Tijburg LB, Wiseman SA, Meijer GW, Weststrate JA. Effects of green tea, black tea and dietary lipophilic antioxidants on LDL oxidizability and atherosclerosis in hypercholesterolaemic rabbits. Atherosclerosis. 1997;135:37-47.
14. Dona M, Dell'Aica I, Calabrese F, et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol. 2003;170:4335-4341.
15. Suzuki M, Yoshino K, Maeda-Yamamoto M, Miyase T, Sano M. Inhibitory effects of tea catechins and O-methylated derivatives of (-)-epigallocatechin-3-O-gallate on mouse type IV allergy. J Agric Food Chem. 2000;48:5649-5653.
16. Paschka AG, Butler R, Young CY-F. Induction of apoptosis in prostate cancer cell lines by the green tea component (-)-epigallocatechin-3-gallate. Cancer Lett. 1998;130:1-7.
17. Roy M, Chakrabarty S, Sinha D, Bhattacharya RK, Siddiqi M. Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutat Res. 2003;523-524:33-41.
18. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Arch Biochem Biophys. 2000;376:338-346.
19. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer. 2003;106:856-862.
20. Benelli R, Vene R, Bisacchi D, Garbisa S, Albini A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol Chem. 2002;383: 101-105.
21. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun. 2000;275: 328-334.
22. Chung JY, Hwang C, Meng X, et al. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. 1999;59: 4610-4617.
23. Arimoto-Kobayashi S, Inada N, Sato Y, et al. Inhibitory effects of (-)-epigallocatechin gallate on the mutation, DNA strand cleavage, and DNA adduct formation by heterocyclic amines. J Agric Food Chem. 2003;51:5150-5153.
24. Sartippour MR, Shao ZM, Heber D, et al. Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr. 2002;132:2307-2311.
25. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Arch Biochem Biophys. 2000;376:338-346.
26. Kao YH, Hiipalla RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology. 2000;141:980-987.
27. Chen L, Lee MJ, Yang CS. Absorption, distribution, and elimination of tea polyphenols in rats. Drug Metab Disp. 1997;25:1045-1050.
28. Chow HH, Cai Y, Albert DS, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and Polyphenon E. Cancer Epidemiol Biomarkers Prev. 2001;10:53-58.
29. Kida K, Suzuki M, Matsumoto N, et al. Identification of biliary metabolites of (-)-epigallocatechin gallate in rats. J Agric Food Chem. 2000;48:4151-4155.
30. Meng X, Sang S, Zhu N, et al. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem Res Toxicol. 2002;15:1042-1050.
31. Lee MJ, Maliakal P, Chen L, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev. 2002;11:1025-1032.
32. Li C, Lee MJ, Sheng S, et al. Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem Res Toxicol. 2000;13:177-184.
33. Saijo R. Isolation and chemical structures of two new catechins from fresh tea leaf. Agric Biol Chem. 1982;46:1969-1971.
34. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Disp. 2003;31:572-579.
35. Okushio K, Suzuki M, Matsumoto N, Nanjo F, Hara Y. Methylation of tea catechins by rat liver homogenates. Biosci Biotechnol Biochem. 1999;63:430-432.
36. Hodgson JM, Burke V, Beilin LJ, Croft KD, Puddey IB. Can black tea influence plasma total homocysteine concentrations? Am J Clin Nutr. 2003;77:907-911.
37. Zhu BT, Patel UK, Cal MX, Conney AH. O-Methylation of tea polyphenols catalyzed by human placental catechol O-methyltransferase. Drug Metab Disp. 2000;28:1024-1030.
38. Meng X, Li MJ, Lee C, et al. Formation and identification of 4′-O-methyl-(2)-epigallocatechin in humans. Drug Metab Disp. 2001;29:789-793.
39. Van Amelsvoort JM, Van Hof KH, Mathot JN, Mulder TP, Wiersma A, Tijburg LB. Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica. 2001;31:891-901.
40. Weinshilboum RM, Otterness M, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999;39:19-52.
41. Shield AJ, Thomae BA, Eckloff BW, Wieben ED, Weinshilboum RM. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatr. 2004;9:151-160.
42. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-4210.
43. Li T, Vallada H, Curtis D, et al. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 1997;7:349-353.
44. McLeod HL, Syvanen AC, Githang'a J, et al. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals. Pharmacogenetics. 1998;8:195-199.
45. Yim DS, Park SK, Yoo KY, et al. Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics. 2001;11:279-286.
46. Haiman CA, Bernstein L, vanDenBerg D, et al. Genetic determinants of mammographic density. Breast Cancer Res. 2002;4:R5. Available at: http://breast-cancer-research.com/content/4/3/R5. Accessed 23 August 2003.
47. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999;59:4870-4875.
48. Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis. 2002;23:329-333.
49. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst. 2001;93:1747-1752.
50. Diet, DNA Methylation and other Epigenetic Events and Cancer Prevention: RFP Competing Supplements. Bethesda, MD: National Cancer Institute and NIH Office of Dietary Supplements. September 27, 2002. PA Number: PAR-02-175.
51. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science. 2003;300:455.
52. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
53. Plumb GW, De Pascual-Teresa S, Santos-Buelga C, Cheynier V, Williamson G. Antioxidant properties of catechins and proanthocyanidins: effect of polymerisation, galloylation and glycosylation. Free Radic Res. 1998;29:351-358.
54. Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol. 2002;40:1745-1750.
55. Nanjo F, Goto K, Seto R, Nanjo F, Goto K, Seto R. Scavenging effects of tea catechins and their derivatives on 1,1-diphenyl-2-picrylhydrazyl radical. Free Radic Biol Med. 1996;21:895-902.
56. Kawase M, Wang R, Shiomi T, Saijo R, Yagi K. Antioxidative activity of (-)-epigallocatechin-3-(3″-O-methyl)-gallate isolated from fresh tea leaf and preliminary results on its biological activity. Biosci Biotechnol Biochem. 2000;64:2218-2220.
57. Sano M, Suzuki M, Miyase T, Yoshino K, Maeda-Yamamoto M. Novel antiallergic catechin derivatives isolated from oolong tea. J Agric Food Chem. 2000;47:1906-1910.
58. Fujimura Y, Tachibana H, Maeda-Yamamoto M, et al. Antiallergic tea catechin, (-)-epigallocatechin-3-O-(3-O-methyl)-gallate, suppresses FcepsilonRI expression in human basophilic KU812 cells. J Agric Food Chem. 2002;50:5729-5734.
59. Tachibana H, Sunada Y, Miyase T, Sano M, Maeda-Yamamoto M, Yamada K. Identification of a methylated tea catechin as an inhibitor of degranulation in human basophilic KU812 cells. Biosci Biotechnol Biochem. 2000;64:452-454.
60. Hong J, Lu H, Meng X, Ryu JH, Hara Y, Yang CS. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res. 2002;62:7241-7246.
61. Saeki K, Hayakawa S, Isemura M, Miyase T. Importance of a pyrogallol-type structure in catechin compounds for apoptosis-inducing activity. Phytochemistry. 2000;53:391-394.
62. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001;276:13322-13330.
63. Smith DM, Wang Z, Kazi A, Li LH, Chan TH, Dou QP. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med. 2002;8:382-392.
64. Yang CS, Chen L, Lee MJ, Balentine D, Kuo MC, Schantz SP. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev. 1998;7:351-354.
65. Wu AH, Tseng CC, van den Berg D, Yu MC. Tea intake, COMT genotype, and breast cancer in Asian-American women. Cancer Res. 2003;63: 7526-7529.
66. Gescher AJ, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol. 2001;2:371-379.
67. Setchell KD, Brown NM, Lydeking-Olsen E. The clinic al importance of the metabolite equol - a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132:3577-3584.
68. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000;130:129-132.
69. Chen J, Giovanucci EL, Hunter DJ. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among US men and women: an example of gene-environment interactions in colorectal tumorigenesis. J Nutr. 1998;129: 560S-564S.